NASDAQ · Medical Devices · USD
Hyperfine, Inc. (HYPR) Stock Analysis
Hyperfine, Inc. (HYPR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
HYPR Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.77
- Previous Close
- $0.77
- Day's Range
- 0.72–0.78
- 52-Week Range
- 0.72–1.94
- Volume
- 500.64K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.46
Valuation
- Market Cap
- $79.14M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 4.79
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.37
Financials (FY)
- Revenue (FY)
- $13.56M+5.22%
- Net Income (FY)
- −$35.57M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −210.75%
- Shares Outstanding
- 90.99M
- 1-Year Return
- −41.70%
Dividend and dates
- Earnings Date
- November 9, 2026
- Avg Volume
- 738.81K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, HYPR closed at $0.75, −41.70% over 1 year.
Hyperfine, Inc. (HYPR) has a market capitalization of $79.14M.
In fiscal 2025, HYPR reported revenue of $13.56M.
HYPR Stock Return by Calendar Year
Hyperfine, Inc. (HYPR) return since Jan 2021: what $10,000 became
- 1 year
- $10,000 $5,830
- −41.70%
- 5 years
- $10,000 $751
- −92.49%
- Since Jan 2021
- $10,000 $732
- −92.68%
If you had invested $10,000 in Hyperfine, Inc. (HYPR) at the close on January 28, 2021, the earliest close on record here, it would have been worth $732 at the close on October 21, 2026: −92.68% in total, −36.64% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −23.77% |
| 2025 | +11.25% |
| 2024 | −21.43% |
| 2023 | +33.33% |
| 2022 | −88.41% |
| 2021 | −28.85% |
As of October 21, 2026.
HYPR Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $13.56M | −$35.57M | −262.3% |
| 2024 | $12.89M | −$40.72M | −315.9% |
| 2023 | $11.03M | −$44.24M | −401.0% |
| 2022 | $6.81M | −$73.16M | −1,073.7% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $13.56M | $6.75M | −$37.09M | −$35.57M | −262.3% |
| 2024 | $12.89M | $5.89M | −$43.22M | −$40.72M | −315.9% |
| 2023 | $11.03M | $4.76M | −$48.12M | −$44.24M | −401.0% |
| 2022 | $6.81M | $907.00K | −$73.87M | −$73.16M | −1,073.7% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
HYPR Valuation vs Medical Devices Median
Median of 145 stocks| Metric | HYPR | Medical Devices median | vs median |
|---|---|---|---|
| P/S ratio | 4.79 | 2.53 | 89% above |
| Profit margin | −210.75% | −14.78% | 196.0 pts below |
Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Full Transcript: Hyperfine Q2 2026 Earnings Call
BenzingaHyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially
InvestorsHubHyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
YahooHyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
YahooHyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est
BenzingaHyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
Yahoo
All 20 articles ↓Show fewer ↑
BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target
BenzingaMedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award
YahooHyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
YahooBTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target
BenzingaHyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
YahooHyperfine Announces Peer-Reviewed Publication Of NEURO PMR Study In Journal Of Neuroimaging
BenzingaHyperfine Receives FDA Clearance For Its Latest Optive AI Software Update; Plans Rollout Of New Software In The U.S. In September
BenzingaHyperfine, Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlphaB. Riley Securities Reiterates Buy on Hyperfine, Lowers Price Target to $1.6
BenzingaHyperfine, Inc. Q2 2026 Earnings Call Summary
MobyHyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
SeekingAlphaHyperfine Inc (HYPR) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% on Strong System ...
YahooHyperfine Q2 Earnings Call Highlights
MarketBeatHyperfine (NASDAQ:HYPR) Q2 Revenue Misses as EPS Matches, But Full-Year Guidance Midpoint Exceeds Estimates
ChartMill
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Medical Devices Stocks
Abbott Laboratories
$173.92B
MDTMedtronic plc.
$119.00B
SYKStryker Corporation
$114.15B
BSXBoston Scientific Corporation
$64.33B
EWEdwards Lifesciences Corporation
$50.95B
GEHCGE HealthCare Technologies Inc.
$31.17B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B











